{
  "clinicalImpactSubmission": [
    {
      "recordStatus": "novel",
      "localID": "civic.mpid:33",
      "localKey": "civic.eid:2997",
      "observedIn": [
        {
          "alleleOrigin": "somatic",
          "affectedStatus": "yes",
          "collectionMethod": "curation"
        }
      ],
      "conditionSet": {
        "condition": [
          {
            "db": "MONDO",
            "id": "0005233"
          }
        ]
      },
      "variantSet": {
        "variant": [
          {
            "hgvs": "ENST00000275493.2:c.2573T>G",
            "gene": [
              {
                "id": 1956
              }
            ]
          }
        ]
      },
      "clinicalImpactClassification": {
        "clinicalImpactClassificationDescription": "Tier I - Strong",
        "assertionTypeForClinicalImpact": "therapeutic: sensitivity/response",
        "drugForTherapeuticAssertion": "afatinib",
        "comment": "Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test",
        "citation": [
          {
            "db": "PubMed",
            "id": "23982599"
          }
        ]
      }
    }
  ]
}
